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abstract
Keywords:

The “Medication-Assisted Therapy for Opioid Addiction” session was chaired by Dr Betty

Buprenorphine

Tai and had three presenters. The presenters (and their topics) were: Dr Andrew J. Saxon

Chronic care model

(methadone and buprenorphine for treatment of opioid addiction and human immuno-

Methadone

deficiency virus risk reduction); Dr Walter Ling (opioid antagonist treatment for opioid

Opioid addiction

addiction); and Dr Betty Tai (chronic care model for substance use disorder).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Currently, three medications are approved by the United
States (US) Food and Drug Administration (FDA) for treating
opioid addiction. Classified by their underlying mechanisms,
these medications include agonist (methadone), partial
agonist (buprenorphine), and antagonist (naltrexone) agents.
The three presentations in this session respectively provided
an overview of agonists and antagonists, and a broader view
of medication-assisted therapy to support a chronic care
model (CCM) for opioid addiction.

2.

Presentations

Dr Andrew Saxon is a professor in the Department of Psychiatry and Behavioral Sciences, University of Washington,
Seattle, WA, USA and the Director of the Center of Excellence
in Substance Abuse Treatment and Education at the Veterans

Affairs Puget Sound Health Care System, Seattle, WA, USA.
Dr Saxon’s talk focused on methadone (a full opioid agonist at
the m receptor) and buprenorphine (a partial opioid agonist).
Methadone typically requires once daily dosing for treatment
of opioid addiction, although in rare circumstances (such as
pregnancy) twice daily dosing is necessary. There is somewhat more flexibility in dosing of buprenorphine. Once daily
dosing works well, but divided doses throughout a single day
or three times weekly dosing are also possible. Buprenorphine
has a superior safety profile compared to methadone.
Methadone is formulated for oral administration and buprenorphine for sublingual administration. A subdermal buprenorphine implant with a 6-month duration of action is being
considered for approval by the US FDA. Both medications
reduce mortality rates and improve other outcomes [e.g., illicit
opioid use, and human immunodeficiency virus (HIV) risk
behavior]. A recently completed study that compared liver
function of patients randomized to methadone or buprenorphine for 6 months of treatment did not find any major liver
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toxicity concerns among either treatment arm. Details of this
presentation can be found in the article by Saxon, Hser,
Woody included in this special issue.
Dr Walter Ling is Professor of Psychiatry at University of
California, Los Angeles (UCLA), CA, USA and Director of the
UCLA Integrated Substance Abuse Programs, CA, USA. Dr Ling
stated that the rationale for the antagonist approach to
treating opioid addiction was originally based on the extinction model of animal experimentation. It was postulated that
by blocking the euphorogenic effects of opioids at the opioid
receptors, opioid use would become nonrewarding, and in
time, animals and humans would cease opioid selfadministration. Results of human laboratory extinction
studies have been strikingly unsuccessful in generalizing into
the real world, and the underlying assumption of the antagonist approach to treating opioid addiction has not been
translated into clinical success. The decision to use or not use
opioids appears to be related to cognition instead of extinction. Still, medication noncompliance has been singled out as
the reason for the clinical failure of the opioid antagonist
approach, and considerable resources have been expended to
develop a sustained-release form of the antagonist naltrexone
to ensure compliance. An injectable form of naltrexone, which
lasts for w4 weeks, and which once administered, is irretrievable, was approved for treatment of alcohol addiction in
2006 and for opioid addiction in 2010. So far, most experience
with sustained-release naltrexone has been in populations of
patients with limited therapeutic options. It remains to be
seen whether the formulation will be a clinical success in
open medical settings affording other treatment choices.
Dr Betty Tai is Director of the Center for Clinical Trials
Network (CTN) at the National Institute on Drug Abuse (NIDA),
Bethesda, MD, USA. Dr Tai’s talk focused on the need for
adopting a CCM to treat substance use disorder (SUD), because
SUD is a chronic brain disease with frequent relapses and
consequences that remain problematic for a long time, even
after discontinuation of use [1]. Six core elements of a CCM
are: (1) healthcare delivery system redesign to plan and
manage preventive care; (2) healthcare organization support
to allow organization-level leadership and resources to sustain CCM; (3) expert-informed decision support to generalist
clinicians to manage cases so that separate specialty treatment is not needed; (4) improved clinical information systems
to track and coordinate care; (5) fostering patient selfmanagement; and (6) linking patients to access community
resources (e.g., peer support groups, exercise programs,
housing, and home care programs) [2].
Using results from the NIDA CTN trials as examples, it has
been shown that medication-assisted therapy is effective in
reducing opioid use, but the relapse rate is generally high
once the medication is stopped at the end of the trial [3,4].
Furthermore, the chronic care model, used in managing
many other chronic illnesses (e.g., diabetes), does more than
just provide reactive care to patients who are seeking treatment. It also provides proactive care for patients at wellness
visits, emphasizing preventive services such as implementation of screening and brief intervention for identified
risky behavior [5]. It also provides opportunities for lifestyle
monitoring and management. Therefore, a CCM is needed to
address addiction properly and effectively [6]. Key factors to

ensure CCM success are: (1) improving providers’ knowledge
of treatment guidelines and skills in following treatment
guidelines; (2) educating, engaging, and supporting patients’
self-management; (3) enhancing the monitoring/reviewing/
following-up of patients with multidisciplinary team service; and (4) leveraging health information technology systems (e.g., electronic health records) to support the first three
elements [7,8]. Current NIDA efforts have been devoted to
developing and adopting digitized screening and brief intervention tools in primary care to define parameters for CCM
research. A longitudinal disease registry for the SUD field is
the critical first step in developing a CCM for SUD treatment.
Although extensive research-based evidence is lacking, the
conceptual and clinical indications suggest that such a CCM
is highly desirable and has the potential to be effective in
early prevention of high-risk substance abuse, reducing
substance use among patients in treatment for SUD, and
improving the quality of care of patients who have other
chronic comorbidity and are negatively affected by unaddressed SUD [9].

3.

Discussion

In the discussion session, the following questions are
addressed.
(1) Why does NIDA CTN not include genetics in their
studies? Although medication trials conducted by NIDA CTN
produce reliable scientific results, it is clear that the same
medication does not work equally for all patients. Genomic
data can shed light on how genetic factors affect patients’
unique responses toward a specific medication; thus, the genetic research component is needed to provide additional
information that can advise effective patient-centered care.
All CTN trials now collect blood samples to enable future genetic investigation. Due to resource limitations, decisions on
whether to analyze the blood genetic elements will be
reviewed and analyzed case by case. Recently, some CTN trials have produced interesting genetic findings [10].
(2) The best medical record system is the one used by US
Veterans Affairs (VA); is there a plan to use it? Yes, Dr Saxon,
who works with the VA system and patient populations, has
used the VA records for his research. CTN is exploring the VA
system and the potential opportunity of moving intervention
trials to real-world VA clinics, and, notably, the possibility of
using VA medical records as the data source for trials.
Opioid addiction, a chronic, relapsing brain disease can be
managed safely and effectively with three US FDA-approved
medications: (1) methadone (a m-receptor agonist); (2) buprenorphine (a m-receptor partial agonist); and (3) injectable
sustained-released naltrexone (a m-receptor antagonist).
These medications reduce mortality rates and improve other
outcomes (e.g., illicit opioid use and HIV risk behavior) in
opioid-addicted patients. In order to enhance their treatment
outcome, we propose that primary care providers adopt the
CCM, which has been widely applied by primary care physicians who manage diabetes and hypertension with success
[11]. The CCM targets the chronic nature of opioid addiction
with a proactive care approach that encompasses preventive
services in primary care settings and is attuned to the
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frequent monitoring of the chronic and relapsing characteristics of opioid addiction. Ideally, the care should be led by the
primary care provider with a single, integrated treatment plan
that addresses and integrates the whole patient’s medical
needs, including the treatment of other comorbid conditions.
The adoption of modern health information technology can
greatly facilitate patient monitoring and CCM care
coordination.
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